Clinical Trials

Phase 1/2 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

296 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

90 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

214 enrolled

Esophageal Neoplasms

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

258 enrolled

Biliary Tract Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

10 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT03314935 2025-08-12

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

GastrointestinalGynecologic

149 enrolled 35 charts

Biliary Tract Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02730546 2025-06-22

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

31 enrolled 20 charts

Stomach Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

51 enrolled

Stomach Neoplasms

NCT04492033 2025-01-27

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

GastrointestinalOther solid neoplasm

41 enrolled

P1b: Advanced Solid Tumors

NCT05640830 2024-11-26

TREAZURE

47 enrolled

HER2-positive Advanced Gastric Cancer

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

DermatologicGastrointestinalGenitourinarySarcoma

358 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT06662669 2024-10-29

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Phase 1/2 Not yet recruiting

120 enrolled

Pancreatic Neoplasms

NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

22 enrolled 17 charts

Resectable Esophageal Cancer

NCT05529667 2024-05-08

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

15 enrolled

Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

73 enrolled 18 charts

Phase 1/2 Enrolling by invitation

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06303583 2024-03-12

CRIS

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT03751761 2024-02-28

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

58 enrolled

Stomach Neoplasms

NCT02735057 2024-01-18

OSAGE

54 enrolled

Esophageal Neoplasms

NCT03618758 2023-12-05

IPLUS

GastrointestinalGynecologic

35 enrolled

Peritoneal Neoplasms, Stomach Neoplasms

NCT05400915 2023-11-13

Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

27 enrolled

Stomach Neoplasms

NCT03649321 2023-11-09

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

9 enrolled 12 charts

Pancreatic Neoplasms

NCT02530437 2023-07-10

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

7 enrolled 11 charts

Phase 1/2 Active not recruiting

Adenocarcinoma Of Esophagus

NCT03544736 2023-03-22

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)

30 enrolled

Esophageal Neoplasms

NCT02983045 2023-03-13

PIVOT-02

BreastDermatologicGastrointestinalGenitourinaryThoracic

557 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03085914 2022-09-23

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

70 enrolled 17 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05535569 2022-09-10

Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

50 enrolled

Stomach Neoplasms

NCT05439993 2022-07-05

Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

42 enrolled

Stomach Neoplasms

NCT05394415 2022-05-27

LATE

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT03707028 2022-04-11

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

12 enrolled

Stomach Neoplasms

NCT03278626 2022-03-28

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

12 enrolled 8 charts

Esophageal Squamous Cell Carcinoma

NCT04506138 2021-12-14

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

46 enrolled

Esophageal Squamous Cell Carcinoma

NCT04526470 2021-08-24

Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

55 enrolled

Stomach Neoplasms

NCT04943653 2021-07-06

IPXELOX

61 enrolled

Stomach Neoplasms

NCT04888663 2021-05-21

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

50 enrolled

Stomach Neoplasms

NCT02562898 2021-05-06

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

18 enrolled 15 charts

Metastatic Pancreatic Adenocarcinoma

NCT03989310 2020-12-23

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

50 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04286711 2020-02-27

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

52 enrolled

Advanced Gastric Cancer

NCT02406170 2019-10-22

REPEAT

47 enrolled

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT04053205 2019-08-12

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

76 enrolled

Advanced Gastric or Gastroesophageal Junction Cancer

NCT04004234 2019-07-09

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

20 enrolled